Analysis of risk factors for malignant mediterranean spotted fever indicates that fluoroquinolone treatment has a deleterious effect

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1821-1830

  Botelho Nevers, Elisabeth ^a,b   Rovery, Clarisse ^a   Richet, Hervé ^a   Raoult, Didier ^a  

^a CNRS   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Rickettsia conorii; Severity; Treatment related

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BETA LACTAM; BILIRUBIN; CHLORAMPHENICOL; COTRIMOXAZOLE; CREATINE KINASE; CREATININE; DOXYCYCLINE; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LACTATE DEHYDROGENASE; MACROLIDE; POTASSIUM; PROTHROMBIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UREA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALCOHOLISM; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIBIOTIC THERAPY; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; ASSISTED VENTILATION; ASTHENIA; BILIRUBIN BLOOD LEVEL; BOUTONNEUSE FEVER; CARDIOVASCULAR DISEASE; CHILD; CHOLESTASIS; CHRONIC BRONCHITIS; COMORBIDITY; CONFUSION; CONJUNCTIVITIS; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEATH; DEEP VEIN THROMBOSIS; DEHYDRATION; DELIRIUM; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DIURESIS; DYSPNEA; EDEMA; FEMALE; FEVER; FIBRINOGEN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERAL CONDITION DETERIORATION; GLASGOW COMA SCALE; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEMATOCRIT; HEMATOLOGIC DISEASE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HUMAN; HYPERTENSION; HYPOACUSIS; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INFECTION RISK; JAUNDICE; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LENGTH OF STAY; LEUKOCYTE COUNT; LEUKOCYTOSIS; LEUKOPENIA; LIVER DISEASE; LUNG EDEMA; LUNG EMBOLISM; LYMPHADENOPATHY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; OBESITY; OXYGEN TENSION; PARTIAL THROMBOPLASTIN TIME; PETECHIA; PHLEBITIS; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; RASH; RETROSPECTIVE STUDY; RICKETTSIA CONORII; RICKETTSIOSIS; RISK ASSESSMENT; SEIZURE; SMOKING; SPLENOMEGALY; STUPOR; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VERTIGO; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BOUTONNEUSE FEVER; CHILD; CHILD, PRESCHOOL; FEMALE; FLUOROQUINOLONES; HUMANS; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RICKETTSIA CONORII; RISK FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 79960473240     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr218     Document Type: Article

References (59)

1. Rovery C, Brouqui P, Raoult D. Questions on Mediterranean spotted fever a century after its discovery. Emerg Infect Dis 2008; 14: 1360-7.
2. Rovery C, Raoult D. Mediterranean spotted fever. Infect Dis Clin North Am 2008; 22: 515-30, ix.
3. Raoult D, Gallais H, Ottomani A et al. [Malignant form of Mediterranean boutonneuse fever. 6 cases]. Presse Med 1983; 12: 2375-8.
4. Raoult D, Zuchelli P, Weiller PJ et al. Incidence, clinical observations and risk factors in the severe form of Mediterranean spotted fever among patients admitted to hospital in Marseilles 1983-1984. J Infect 1986; 12: 111-6.
5. Raoult D, Weiller PJ, Chagnon A et al. Mediterranean spotted fever: clinical, laboratory and epidemiological features of 199 cases. Am J Trop Med Hyg 1986; 35: 845-50.
6. Martin FA, Juarez FC, Calbo TF et al. [Clinico-epidemiological study of 164 cases of boutonneuse fever]. Rev Clin Esp 1985; 176: 333-9.
7. Amaro M, Bacellar F, Franca A. Report of eight cases of fatal and severe Mediterranean spotted fever in Portugal. Ann N Y Acad Sci 2003; 990: 331-43.
8. Mouffok N, Parola P, Lepidi H et al. Mediterranean spotted fever in Algeria-new trends. Int J Infect Dis 2009; 13: 227-35.
9. Sousa R, Franca A, Doria NS et al. Host- and microbe-related risk factors for and pathophysiology of fatal Rickettsia conorii infection in Portuguese patients. J Infect Dis 2008; 198: 576-85.
10. Raoult D, Parola P. Rocky Mountain spotted fever in the USA: a benign disease or a common diagnostic error? Lancet Infect Dis 2008; 8: 587-9.
11. de Sousa R, Nobrega SD, Bacellar F et al. Mediterranean spotted fever in Portugal: risk factors for fatal outcome in 105 hospitalized patients. Ann N Y Acad Sci 2003; 990: 285-94.
12. Zhu Y, Fournier PE, Eremeeva M et al. Proposal to create subspecies of Rickettsia conorii based on multi-locus sequence typing and an emended description of Rickettsia conorii. BMC Microbiol 2005; 5: 11.
13. Fournier PE, Raoult D. Intraspecies diversity of Rickettsia conorii. J Infect Dis 2009; 199: 1097-8.
14. Font-Creus B, Espejo AE, Munoz ET et al. [Mediterranean boutonneuse fever. Study of 246 cases]. Med Clin (Barc) 1991; 96: 121-5.
15. de Sousa R, Ismail N, Nobrega SD et al. Intralesional expression of mRNA of interferon-gamma, tumor necrosis factor-alpha, interleukin-10, nitric oxide synthase, indoleamine-2,3-dioxygenase, and RANTES is a major immune effector in Mediterranean spotted fever rickettsiosis. J Infect Dis 2007; 196: 770-81.
16. Fagon JY, Chastre J, Novara A et al. Characterization of intensive care unit patients using a model based on the presence or absence of organ dysfunctions and/or infection: the ODIN model. Intensive Care Med 1993; 19: 137-44.
17. Raoult D, Drancourt M. Antimicrobial therapy of rickettsial diseases. Antimicrob Agents Chemother 1991; 35: 2457-62.
18. Raoult D, Maurin M. Other Rickettsia species. In: Yu V, Weber R, Raoult D, eds. Antimicrobial Therapy and Vaccines. New York: Apple Trees Productions, LLC, 2002; 913-21.
19. Holman RC, Paddock CD, Curns AT et al. Analysis of risk factors for fatal Rocky Mountain spotted fever: evidence for superiority of tetracyclines for therapy. J Infect Dis 2001; 184: 1437-44.
20. Maurin M, Raoult D. Rickettsia prowazekii (epidemic typhus and Brill-Zinsser disease). In: Yu V, Weber R, Raoult D, eds. Antimicrobial therapy and vaccines. New York: Apple Trees Productions, LLC, 2002; 893-7.
21. Maurin M, Raoult D. Rickettsia typhi (murine typhus). In: Yu V, Weber R, Raoult D, eds. Antimicrobial Therapy and Vaccines. New York: Apple Trees Productions, LLC, 2002; 907-11.
22. Walker DH, Sexton DJ. Rickettsia rickettsii (Rocky Mountain spotted fever). In: Yu V, Weber R, Raoult D, eds. Antimicrobial Therapy and Vaccines. New York: Apple Trees Productions, LLC, 2002; 899-906.
23. Shaked Y, Samra Y, Maier MK et al. Relapse of rickettsial Mediterranean spotted fever and murine typhus after treatment with chloramphenicol. J Infect 1989; 18: 35-7.
24. Fishbein DB, Frontini MG, Giles R et al. Fatal cases of Rocky Mountain spotted fever in the United States, 1981-1988. Ann N Y Acad Sci 1990; 590: 246-7.
25. Huys J, Freyens P, Kayihigi J et al. Treatment of epidemic typhus. A comparative study of chloramphenicol, trimethoprimsulphamethoxazole and doxycycline. Trans R Soc Trop Med Hyg 1973; 67: 718-21.
26. Rolain JM, Maurin M, Vestris G et al. In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials. Antimicrob Agents Chemother 1998; 42: 1537-41.
27. Cascio A, Colomba C, Antinori S et al. Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial. Clin Infect Dis 2002; 34: 154-8.
28. Cascio A, Colomba C, Di Rosa D et al. Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial. Clin Infect Dis 2001; 33: 409-11.
29. Ruiz Beltran R, Herrero Herrero JI. Evaluation of ciprofloxacin and doxycycline in the treatment of Mediterranean spotted fever. Eur J Clin Microbiol Infect Dis 1992; 11: 427-31.
30. Raoult D, Gallais H, De Micco P et al. Ciprofloxacin therapy for Mediterranean spotted fever. Antimicrob Agents Chemother 1986; 30: 606-7.
31. Gudiol F, Pallares R, Carratala J et al. Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever. Antimicrob Agents Chemother 1989; 33: 987-8.
32. Fournier PE, Raoult D. Suicide PCR on skin biopsy specimens for diagnosis of rickettsioses. J Clin Microbiol 2004; 42: 3428-34.
33. La Scola B, Raoult D. Diagnosis of Mediterranean spotted fever by cultivation of Rickettsia conorii from blood and skin samples using the centrifugation-shell vial technique and by detection of R. conorii in circulating endothelial cells: a 6-year follow-up. J Clin Microbiol 1996; 34: 2722-7.
34. Raoult D, de Micco C, Gallais H et al. Laboratory diagnosis of Mediterranean spotted fever by immunofluorescent demonstration of Rickettsia conorii in cutaneous lesions. J Infect Dis 1984; 150: 145-8.
35. Raoult D, Tissot Dupont H, Caraco P et al. Mediterranean spotted fever in Marseille: descriptive epidemiology and the influence of climatic factors. Eur J Epidemiol 1992; 8: 192-7.
36. Teysseire N, Raoult D. Comparison of Western immunoblotting and microimmunofluorescence for diagnosis of Mediterranean spotted fever. J Clin Microbiol 1992; 30: 455-60.
37. La Scola B, Raoult D. Laboratory diagnosis of rickettsioses: current approaches to diagnosis of old and new rickettsial diseases. J Clin Microbiol 1997; 35: 2715-27.
38. Raoult D, Jean-Pastor MJ, Xeridat B et al. [Mediterranean boutonneuse fever. Apropos of 154 recent cases]. Ann Dermatol Venereol 1983; 110: 909-14.
39. Anton E, Font B, Munoz T et al. Clinical and laboratory characteristics of 144 patients with Mediterranean spotted fever. Eur J Clin Microbiol Infect Dis 2003; 22: 126-8.
40. Font-Creus B, Bella-Cueto F, Espejo-Arenas E et al. Mediterranean spotted fever: a cooperative study of 227 cases. Rev Infect Dis 1985; 7: 635-42.
41. Cahuana A, Losada I, Galceran L et al. [Mediterranean boutonneuse fever in children. Study of 139 cases]. An Esp Pediatr 1984; 21: 642-7.
42. Lopez PP, Munoz ET, Espejo AE et al. [Mediterranean spotted fever in childhood. Prospective study of 130 cases]. An Esp Pediatr 1988; 28: 293-6.
43. Cascio A, Dones P, Romano A et al. Clinical and laboratory findings of boutonneuse fever in Sicilian children. Eur J Pediatr 1998; 157: 482-6.
44. Colomba C, Saporito L, Polara VF et al. Mediterranean spotted fever: clinical and laboratory characteristics of 415 Sicilian children. BMC Infect Dis 2006; 6: 60.
45. Bellissima P, Bonfante S, La Spina G et al. [Complications of Mediterranean spotted fever]. Infez Med 2001; 9: 158-62.
46. Punda-Polic V, Klismanic Z, Capkun V et al. Demographic and epidemiologic features of Mediterranean spotted fever cases in the region of Split, Croatia. Ann N Y Acad Sci 2003; 990: 143-8.
47. Drancourt M, Raoult D, Harle JR et al. Biological variations in 412 patients with Mediterranean spotted fever. Ann N Y Acad Sci 1990; 590: 39-50.
48. Demeester R, Claus M, Hildebrand M et al. Diversity of life-threatening complications due to Mediterranean spotted fever in returning travelers. J Travel Med 2010; 17: 100-4.
49. Raoult D, Roussellier P, Galicher V et al. In vitro susceptibility of Rickettsia conorii to ciprofloxacin as determined by suppressing lethality in chicken embryos and by plaque assay. Antimicrob Agents Chemother 1986; 29: 424-5.
50. Romdhane FB, Loussaief C, Toumi A et al. Mediterranean spotted fever: a report of 200 cases in Tunisia. Clin Microbiol Infect 2009; 15 Suppl 2: 209-10.
51. Zanetti G, Francioli P, Tagan D et al. Imported epidemic typhus. Lancet 1998; 352: 1709.
52. Laferl H, Fournier PE, Seiberl G et al. Murine typhus poorly responsive to ciprofloxacin: a case report. J Travel Med 2002; 9: 103-4.
53. Owens RC Jr, Donskey CJ, Gaynes RP et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S19-31.
54. Pandey DP, Gerdes K. Toxin-antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes. Nucleic Acids Res 2005; 33: 966-76.
55. Gerdes K, Christensen SK, Lobner-Olesen A. Prokaryotic toxin-antitoxin stress response loci. Nat Rev Microbiol 2005; 3: 371-82.
56. Goerke C, Koller J, Wolz C. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 171-7.
57. Zhang X, McDaniel AD, Wolf LE et al. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000; 181: 664-70.
58. Adams DA, Riggs MM, Donskey CJ. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob Agents Chemother 2007; 51: 2674-8.
59. Bella F, Font B, Uriz S et al. Randomized trial of doxycycline versus josamycin for Mediterranean spotted fever. Antimicrob Agents Chemother 1990; 34: 937-8.